布地奈德联合阿奇霉素序贯疗法对肺炎支原体肺炎患儿细胞免疫及肺功能状态影响研究.docVIP

布地奈德联合阿奇霉素序贯疗法对肺炎支原体肺炎患儿细胞免疫及肺功能状态影响研究 　　[摘要] 目的 分析布地奈德联合阿奇霉素序贯疗法对肺炎支原体肺炎患儿细胞免疫及肺功能状态的影响研究。 方法 选取2015年8月～2016年10月来我院就诊的164例支原体肺炎患儿作为本次实验的研究对象，将其随机分为两组，即研究组（n=84例）和对照组（n=80例），其中对照组患儿采用阿奇霉素序贯疗法，而研究组患儿采用布地奈德联合阿奇霉素序贯疗法，对比两组患儿临床疗效、细胞免疫水平及肺功能状态。 结果 研究组患儿治疗有效率96.43%明显高于对照组77.50%，治疗后，研究组患儿细胞免疫、肺功能均显著优于对照组，差异有统计学意义（P0.05）。 结论 布地奈德联合阿奇霉素序贯疗法可提高临床疗效，改善患儿的细胞因子水平，改善支原体肺炎患儿的肺功能，且安全性较好，值得临床推广。 　　[关键词] 布地奈德；阿奇霉素；支原体肺炎；细胞免疫；肺功能 　　[中图分类号] R725.6 [文献标识码] A [文章编号] 2095-0616（2017）15-20-04 　　[Abstract] Objective To research the influence of cellular immunity and pulmonary function status of budesonide combined with zaithromycin sequential therapy in the treatment of mycoplasma pneumonia in children. Methods 164 mycoplasma pneumonia cases in our hospital from August 2015 to October 2016 were selected as objects， which were divided into control group（n=84） and research group（n=80） randomly ， the patients of control group were treated by zaithromycin sequential therapy ， while the patients of research group were treated by budesonide combined with zaithromycin sequential therapy， the clinical efficacy， cellular immunity and pulmonary function of patients in two groups were compared. Results The effective rate of research group was 96.43%， which was much higher than control group（77.50%）. The cellular immunity and pulmonary function after treatment of research group were much better than control group，and the difference was statistically significant （P0.05）. Conclusion Budesonide combined azithromycin sequential therapy can improve the clinical curative effect， improve the patients level of cytokines， improve lung function in children with mycoplasma pneumonia and have better safety， and worth clinical promotion. 　　[Key words] Budesonide； Aithromycin；Mycoplasma pneumonia； Cellular immunity； Pulmonary function 　　作?樵?发性非典型肺炎，小儿支原体肺炎是由支原体感染导致，全身支原体感染主要通过血液传播，威胁患儿的生命健康[1]。作为常见的婴幼儿呼吸道传播性疾病，30%的小儿肺炎为小儿支原体肺炎。由于患儿的抵抗力、机体免疫力较差，免疫系统未完全发育[2]，因此，需采用有效、积极、安全的治疗措施治疗[3]，临床上目前提出阿奇霉素序贯疗法进行小儿肺炎支原体治疗[4]